Because Smad3, a downstream effector of TGF-β signalling, is a ‘master regulator' of cell fate16, it has been of great interest to determine whether Smad3 promotes the maintenance of ‘stemness' in vivo, including CML cell stemness. The gene discussed is TGFB1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.